Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

Journal of the cardiometabolic syndrome

Volumn 2, Issue 2, 2007, Pages 149-150

  McFarlane, Samy I ^a   Provilus, Alfrede ^a   Shin, John J ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; RAMIPRIL; ROSIGLITAZONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREDIABETIC STATE; RAMIPRIL; THIAZOLIDINEDIONES;

EID: 34548441619     PISSN: 15594564     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1559-4564.2007.06663.x     Document Type: Article

References (0)